Will Cardiovascular Systems, Inc. ($CSII) Beat Analysts View?

131

Cardiovascular Systems, Inc. (NASDAQ:CSII) is set to announce fourth quarter earning results on Tuesday 4th August 2020, after market close.

Analysts surveyed by Thomson Reuters are predicting, CSII to report 4Q20 loss of $ 0.46 per share.

For the full year, analysts anticipate top line of $ 232.32 million, while looking forward to loss of $ 0.82 per share bottom line.

The Company Outlook

Full Year 2020 topline are forecasted in a range of$ 280.00 million ~ $ 283.00 million

Click Here For More Historical Outlooks Of Cardiovascular Systems, Inc.

Previous Quarter Performance

Cardiovascular Systems, Inc. unwinded loss for the third quarter of $ 0.08 per share, from the revenue of $ 61.17 million. The quarterly earnings while revenues compared with the same quarter last year.
Street analysts expected Cardiovascular Systems, Inc. to report loss of $ 0.08 per share on revenue of $ 65.80 million for the third quarter. The bottom line results street analysts by $ 0 or , at the same time, top line results fell short of analysts by $ 4.63 million or 7.04 percent.

Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!

Click Here For More Historical Earnings Of Cardiovascular Systems, Inc.

Stock Performance

According to the previous trading day, closing price of CSII was $ 31.25, representing a 20.19 % increase from the 52 week low of $ 26.00 and a 43.41 % decrease over the 52 week high of $ 55.22.

The company has a market capital of $ 1.23 billion and is part of the Healthcare sector and Medical Devices industry.

[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CSII” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]

Recent Analyst recommendations

  • On 11th June 2020, upgraded by Needham & Company LLC to Buy from Hold rating.
Conference Call

Cardiovascular Systems, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.csi360.com

Cardiovascular Systems, Inc., a medical device company, develops, manufactures, and commercializes various devices to treat vascular and coronary diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary OAS, a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions.